PATENT CLAIM ANALYSIS

Application Number: 15758187
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-01
Patent Classification: ["424", "185100"]

Abstract:
The present disclosure relates to CCL22 as a novel T cell target in cancer immunosuppression.

Claim (Index 3):
The vaccine composition according to  claim 1 , wherein said immunogenically active peptide fragment comprises or consists of\n a) a consecutive sequence in the range of 8 to 11 amino acids of SEQ ID NO: 12 or SEQ ID NO: 15, such as a consecutive sequence of 9 to 10 amino acids of SEQ ID NO: 12 or SEQ ID NO: 15; or b) a consecutive sequence in the range of 20 to 25 amino acids of SEQ ID NO: 12, such as a consecutive sequence of 22 to 24 amino acids of SEQ ID NO: 12 or SEQ ID NO: 15; or c) a functional homologue of a) or b) wherein at the most two amino acids have been substituted.

Metadata:
- Claim Count in Document: 16.0
- Percentile: 90.0
- Lexical Diversity: 1.0
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14352407', '15231075', '12988124', '10580016', '13031396']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7951790651627597
- 35 USC 102 Novelty (BERT): 0.5652295307411068
- Combined Prediction Score: 0.7721841117205944
- Mean Citation Score: 418.076916
- Max Citation Score: 477.45294
- Similarity Product: 351.0622983556653

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test